DUBLIN--(BUSINESS WIRE)--Dublin - Research and Markets (http://www.researchandmarkets.com/research/4c1eea86/hong_kong_pharmace) has announced the addition of the "Hong Kong Pharmaceuticals and Healthcare Report Q2 2012" report to their offering.
Business Monitor International's Hong Kong Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Hong Kong's pharmaceuticals and healthcare industry.
BMI View: Despite an increasingly ageing population (consequently increasing burden of noncommunicable diseases) Hong Kong will only be moderately attractive to investors given its small market size. While the dominance of patented medicines is set to continue in the medium term, cost-containment measures will increasingly prioritise the use of generic drugs in the public sector. BMI also note that the anticipation of a year of the dragon baby boom can bring about short-term opportunities for pharmaceutical companies with infant care products as part of their portfolios.
Headline Expenditure Projections:
- Pharmaceuticals: HKD8.66bn (US$1.11bn) in 2011 to HKD9.32bn (US$1.20bn) in 2012; 7.6% in local currency terms and 7.8% in US dollar terms.
- Healthcare: HKD86.24bn (US$11.08bn) in 2011 to HKD89.68bn (US$11.53bn) in 2012; 4.0% in local currency terms and 4.1% in US dollar terms.
- Medical devices: HKD4.22bn (US$542mn) in 2011 to HKD4.37bn (US$562mn) in 2012; 3.5% in local currency terms and 3.6% in US dollar terms
Key Topics Covered:
Executive Summary
SWOT Analysis
Pharmaceutical Risk/Reward Ratings
Industry Trends And Developments
Industry Forecast Scenario
Key Growth Factors - Macroeconomic
Key Risks To BMI's Forecast Scenario
Company Profiles
Country Snapshot: Hong Kong Demographic Data
Glossary
BMI Methodology
Companies Mentioned:
- Wuyi International Pharmaceutical
- CK Life Sciences
- South Asia Pharmamedic
- C&Y Pharmaceutical Investment
- Vida Laboratories
- GlaxoSmithKline
- Pfizer
- Sanofi
- Merck & Co
- Novartis
For more information visit http://www.researchandmarkets.com/research/4c1eea86/hong_kong_pharmace